Gewandter, Jennifer S. http://orcid.org/0000-0001-7938-6775
Kleckner, Amber S. http://orcid.org/0000-0002-5088-1139
Marshall, James H.
Brown, Jeffrey S.
Curtis, Lesley H.
Bautista, Javier
Dworkin, Robert H.
Kleckner, Ian R. http://orcid.org/0000-0002-9828-9986
Kolb, Noah
Mohile, Supriya G.
Mustian, Karen M.
Funding for this research was provided by:
National Institutes of Health (NIH U24AT009676, NIH/NCI UG1CA189961)
Article History
Received: 29 May 2019
Accepted: 28 August 2019
First Online: 7 September 2019
Compliance with ethical standards
:
: Jennifer S. Gewandter has received consulting income in the past 36 months from MundiPharma, Disarm Therapeutics, Asahi Kasei Pharma, and SK Life Science. Ian R. Kleckner has received funding from the National Institutes of Health (K07CA221931). Robert H. Dworkin has received in the past 36 months research grants and contracts from US Food and Drug Administration and US National Institutes of Health, and compensation for consulting on clinical trial methods from Abide, Adynxx, Analgesic Solutions, Aptinyx, Asahi Kasei, Astellas, AstraZeneca, Biogen, Biohaven, Boston Scientific, Braeburn, Celgene, Centrexion, Chromocell, Clexio, Concert, Decibel, Dong-A, Eli Lilly, Eupraxia, Glenmark, Grace, Hope, Immune, Lotus Clinical Research, Mainstay, Neumentum, NeuroBo, Novaremed, Novartis, Pfizer, Phosphagenics, Quark, Reckitt Benckiser, Regenacy (also equity), Relmada, Sandoz, Scilex, Semnur, Sollis, Teva, Theranexus, Trevena, and Vertex.
: The Harvard Pilgrim Health Care Institutional Review Board (IRB) determined that the project does not meet the definition of human subject research under the purview of the IRB according to federal regulations.